Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00617799 · ClinicalTrials.gov registry record
Biomarkers That Predict Response to High-Dose Aldesleukin in Metastatic Kidney Cancer or Metastatic Melanoma
A clinical trial, sponsored by University of Nebraska.
- Completed
- Registry status
- 15
- Enrollment target
NCT00617799 is a clinical trial that has completed, run by University of Nebraska. The registered enrollment target is 15 participants.
The verdict
NCT00617799 has completed, sponsored by University of Nebraska.
- COMPLETED
- Registry status
- 15 participants
- Enrollment target
Study Summary
RATIONALE: Studying samples of blood from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. It may also help doctors predict how patients will respond to treatment. PURPOSE: This research study is looking at biomarkers that predict response to high-dose aldesleukin in patients with metastatic kidney cancer or metastatic melanoma.
Interventions
- GENETIC gene expression analysis
- GENETIC mutation analysis
- OTHER flow cytometry
- BIOLOGICAL aldesleukin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2007-10-02 |
| Est. Completion | 2010-04-16 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00617799
The ClinicalTrials.gov registry entry for NCT00617799 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Nebraska, which has 407 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which gene expression analysis is the first listed.
NCT00617799 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00617799 about?
NCT00617799 is a clinical study titled "Biomarkers That Predict Response to High-Dose Aldesleukin in Metastatic Kidney Cancer or Metastatic Melanoma". RATIONALE: Studying samples of blood from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. It may also help doctors predict how patients will respond to treatment. PURPOSE: This research study is looking at...
What is the current status of trial NCT00617799?
This trial is currently completed. The enrollment target is 15 participants. The study started on 2007-10-02. Estimated completion is 2010-04-16.
What interventions are being tested in trial NCT00617799?
The interventions under investigation include: gene expression analysis (GENETIC), mutation analysis (GENETIC), flow cytometry (OTHER), aldesleukin (BIOLOGICAL).
Who is sponsoring clinical trial NCT00617799?
This trial is sponsored by University of Nebraska, which has 407 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.